{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.9","upperLimit":"7.4","value":"5.6"},{"groupId":"OG001","lowerLimit":"7.4","upperLimit":"13.2","value":"11.1"},{"groupId":"OG002","lowerLimit":"7.4","upperLimit":"19.2","value":"10.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"41"}],"units":"Participants"}],"title":"Investigator assessed"},{"categories":[{"measurements":[{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"4.7","upperLimit":"NA","value":"7.6"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"5.6","upperLimit":"NA","value":"9.5"},{"comment":"NA: Not estimable due to insufficient number of participants with events","groupId":"OG002","lowerLimit":"6.7","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"33"}],"units":"Participants"}],"title":"BICR assessed"}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"54"}],"units":"Participants"}],"description":"Duration of response for participants with either a CR (the disappearance of all target lesions. Any pathological lymph nodes must be \\<10 mm in the short axis.) or PR (at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters \\[e.g., percent change from Baseline\\]) is defined as the time from the first documented evidence of a PR or CR until the first documented sign of disease progression (PD) or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received dabrafenib 150 mg gelatin capsules BID.","id":"OG000","title":"Part C: Dabrafenib 150 mg"},{"description":"Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.","id":"OG001","title":"Part C: Dabrafenib 150 mg + Trametinib 1 mg"},{"description":"Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.","id":"OG002","title":"Part C: Dabrafenib 150 mg + Trametinib 2 mg"}],"paramType":"MEDIAN","populationDescription":"ITT Population. Only those participants who had a CR or PR were analyzed for duration of response.","reportingStatus":"POSTED","timeFrame":"First documented evidence of PR or CR until the date of the first documented sign of disease progression or the date of death due to any cause (up to approximately 19 months)","title":"Part C (Randomized): Duration of Response as Assessed by the Investigator and Blinded Independent Central Review (BICR)","type":"PRIMARY","unitOfMeasure":"Months"}